Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use-Reference-Cited by-同舟云学术

Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use

Published:2016-07 Issue: Volume:104 Page:226-234
ISSN:0939-6411
Container-title:European Journal of Pharmaceutics and Biopharmaceutics
language:en
Short-container-title:European Journal of Pharmaceutics and Biopharmaceutics

Author:

ter Weele Eva J.,Terwisscha van Scheltinga Anton G.T.,Linssen Matthijs D.,Nagengast Wouter B.,Lindner Ingo,Jorritsma-Smit Annelies,de Vries Elisabeth G.E.,Kosterink Jos G.W.,Lub-de Hooge Marjolijn N.

Funder

Center for Translational Molecular Medicine, project Mammoth

Dutch Cancer Society

Advanced Investigator ERC grant (OnQview)

Publisher

Elsevier BV

Subject

Pharmaceutical Science,General Medicine,Biotechnology

Reference23 articles.

1. Optical innovations in surgery;de Boer;Br. J. Surg.,2015

2. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies;Terwisscha van Scheltinga;J. Nucl. Med.,2011

3. Everolimus reduces 89Zr-bevacizumab tumor uptake in patients with neuroendocrine tumors;van Asselt;J. Nucl. Med.,2014